BioPharma Deals Random thoughts about the biopharmaceutical industry
OVERVIEW
BIOPHARMADEALS.WORDPRESS.COM TRAFFIC
Date Range
Date Range
Date Range
LINKS TO WEBSITE
A blog to discuss biotechnology and pharmaceutical financing deals, including venture capital funding, mergers and acquisitions, and licensing deals. Posted on Thursday, December 24, 2009 - 2 comments. Is The Risk Worth The Reward? Posted on Saturday, November 18, 2006 - 1 comments. One thing to keep in mind is that the higher premiums are only part of the picture. It is often overlooked that pharmaceutical companie.
This blog is to share opinions and ideas that enhance valuations of emerging, venture-financed companies that are geared toward creating wealth in the near future. , we advise clients on such matters for a fee. I write a blog on part time education too. Click here to go there. Interested in IP Valuation? Please click here and take a moment to complete our valuation survey. It helps everyone! Monday, November 22, 2010.
Thursday, December 24, 2009. Monday, September 28, 2009. Branding Emerging Bioscience Companies to Attract Investors. Sasha Strauss, Managing Director at Innovation Protocol. Gave a very interesting presentation at the SoCalBio Investor Conference. He argues that even start-ups need to consider a branding strategy right from the start. Given the limited capital, does it make sense for a start-up to spend money on branding? Monday, September 21, 2009.
WHAT DOES BIOPHARMADEALS.WORDPRESS.COM LOOK LIKE?
BIOPHARMADEALS.WORDPRESS.COM SERVER
BROWSER IMAGE
SERVER SOFTWARE
We discovered that biopharmadeals.wordpress.com is weilding the nginx os.HTML TITLE
BioPharma Deals Random thoughts about the biopharmaceutical industryDESCRIPTION
Random thoughts about the biopharmaceutical industryPARSED CONTENT
The site had the following in the homepage, "Random thoughts about the biopharmaceutical industry." I noticed that the web site stated " An Example of Financing Risk in a Microcap Biotech Stock." They also stated " I previously blogged about financing risks. Associated with microcap biotech companies. In this post, I wanted examine a real-life example of a microcap biotech that recently had to raise capital. On February 12th, ImmunoCellular Therapeutics IMUC raised approximately 14. If you look at IMUCs 10-Q. Management had stated that the Phase 3 trial could enroll 600 patients."ANALYZE MORE BUSINESSES
Always ensuring highest quality and incomparable service. Learn More About Services for Pharmaceutical and Biotech. Always ensuring highest quality and incomparable service. Learn More About Services for Medical Devices. Always ensuring highest quality and incomparable service.
Lundbeck bulks up neuro pipeline with Prexton buy. As part of the deal, Lundbeck will add a first-in-class small-molecule compound, foliglurax, to its growing CNS repertoire. Ionis taps majority-owned Akcea to launch inotersen. Solid Biosciences reveals upgraded clinical hold for gene therapy. Novartis splits operations unit as part of leadership reshuffle. Alexions follow-on stacks up to Soliris. Pharma pay to hospitals in 340B under fire at Senate panel. Opioid manufacturers paid physicians .
EZ Waste Solvent Waste System. We are committed to working closely with you to ensure our solution meets your process needs and constraints. We are committed to providing the most cost effective.
Biopharma Informatic, Inc, is a group of dedicated and experienced investigators based in Texas, Alabama and Florida. See our network of sites ready to execute studies for sponsors and CROs. Read our blog to learn even more about cutting-edge treatments and industry news.